Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom

Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes

(2016) James J. Chamberlain et al.   ANNALS OF INTERNAL MEDICINE

Medication Adherence Affects Risk of New Diabetes Complications

(2016) Scot H. Simpson et al.   ANNALS OF PHARMACOTHERAPY

Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study

(2016) Robert R. Henry et al.   Diabetes Technology & Therapeutics

Perceptions and experiences of taking oral medications for the treatment of Type 2 diabetes mellitus: a systematic review and meta-synthesis of qualitative studies

(2016) J. McSharry et al.   DIABETIC MEDICINE

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM –2016 EXECUTIVE SUMMARY

(2016) Alan J. Garber et al.   Endocrine Practice

Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants

(2016)   LANCET

Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan

(2016) Heather Gelhorn et al.   Patient Preference and Adherence

Associations between adherence and outcomes among older, type 2 diabetes patients: evidence from a Medicare Supplemental database

(2016) Maureen Lage et al.   Patient Preference and Adherence

Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors

(2016) William Polonsky et al.   Patient Preference and Adherence

Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study

(2016) Manuj Sharma et al.   BMJ Open

A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany

(2016) Christine Poulos et al.   Therapeutic Advances in Neurological Disorders

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany

(2016) Karel Kostev et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study

(2016) William Saunders et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Impact of Medication Adherence and Persistence on Clinical and Economic Outcomes in Patients with Type 2 Diabetes Treated with Liraglutide: A Retrospective Cohort Study

(2015) Erin K. Buysman et al.   ADVANCES IN THERAPY

Prevalence, incidence and concomitant co-morbidities of type 2 diabetes mellitus in South Western Germany - a retrospective cohort and case control study in claims data of a large statutory health insurance

(2015) Michael W. J. Boehme et al.   BMC PUBLIC HEALTH

Initial therapy, persistence and regimen change in a cohort of newly treated type 2 diabetes patients

(2015) Ronan T. Grimes et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes

(2015) A. Brett Hauber et al.   CURRENT MEDICAL RESEARCH AND OPINION

GLP-1 Receptor Agonists

(2015) Curtis Triplitt et al.   DIABETES EDUCATOR

Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists

(2015) Sten Madsbad   DIABETES OBESITY & METABOLISM

Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK

(2015) Heather Gelhorn et al.   Patient Preference and Adherence

A Survey of Patient Preferences for Oral Antihyperglycemic Therapy in Patients with Type 2 Diabetes Mellitus

(2015) A. Brett Hauber et al.   Diabetes Therapy

A Survey of Patient Preferences for Oral Antihyperglycemic Therapy in Patients with Type 2 Diabetes Mellitus

(2015) A. Brett Hauber et al.   Diabetes Therapy

Retrospective Study of Adherence to Glucagon-like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes Mellitus in the United States

(2014) Stephen S. Johnston et al.   ADVANCES IN THERAPY

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

GLP-1 Receptor Agonists for Type 2 Diabetes Mellitus: Recent Developments and Emerging Agents

(2014) Jennifer M. Trujillo et al.   PHARMACOTHERAPY

Prevalence and Incidence of Diabetes in Stockholm County 1990-2010

(2014) Tomas Andersson et al.   PLoS One

The association between the measurement of adherence to anti-diabetes medicine and the HbA1c

(2014) Sheila A. Doggrell et al.   International Journal of Clinical Pharmacy

GLP-1 receptor agonists: a review of head-to-head clinical studies

(2014) Jennifer M. Trujillo et al.   Therapeutic Advances in Endocrinology and Metabolism

Individualizing Glycemic Targets in Type 2 Diabetes Mellitus: Implications of Recent Clinical Trials

(2013) Faramarz Ismail-Beigi et al.   ANNALS OF INTERNAL MEDICINE

Predictors of medication adherence in patients with type 2 diabetes mellitus

(2013) Suellen M. Curkendall et al.   CURRENT MEDICAL RESEARCH AND OPINION

Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: Patient preferences

(2013) A.F. Mohamed et al.   DIABETES & METABOLISM

Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK

(2013) H. L. Gelhorn et al.   DIABETES OBESITY & METABOLISM

Global estimates of diabetes prevalence for 2013 and projections for 2035

(2013) L. Guariguata et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Constructing Experimental Designs for Discrete-Choice Experiments: Report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force

(2013) F. Reed Johnson et al.   VALUE IN HEALTH

A discrete choice experiment to determine patient preferences for injection devices in multiple sclerosis

(2013) S. L. Shingler et al.   JOURNAL OF MEDICAL ECONOMICS

Adherence to Therapies in Patients with Type 2 Diabetes

(2013) Luis-Emilio García-Pérez et al.   Diabetes Therapy

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis

(2012) C. F. Deacon et al.   DIABETES OBESITY & METABOLISM

A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo

(2012) D. A. Scott et al.   DIABETES OBESITY & METABOLISM

A Review of Diabetes Treatment Adherence and the Association with Clinical and Economic Outcomes

(2011) Carl Asche et al.   CLINICAL THERAPEUTICS

Patient preferences for diabetes management among people with type 2 diabetes in Denmark – a discrete choice experiment

(2011) Mette Bøgelund et al.   CURRENT MEDICAL RESEARCH AND OPINION

National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants

(2011) Goodarz Danaei et al.   LANCET

Conjoint Analysis Applications in Health—a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force

(2011) John F.P. Bridges et al.   VALUE IN HEALTH

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients with Type 2 Diabetes

(2009) Kazuya IWAMOTO et al.   ENDOCRINE JOURNAL

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

(2008) Daniel J Drucker et al.   LANCET